the aid library

LIST OPTIONS

Filter

2629

非传染性疾病预防和控制：资源匮乏地区初级卫生保健指南 2012

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The document, titled "Prevention and Control of Noncommunicable Diseases: Guidelines for Primary Health Care in Low-Resource Settings," provides the World Health Organization's (WHO) recommendations... more

الوقاية من األمراض غير السارية ومكافحتها: المبادئ التوجيهية للرعاية الصحية األولية في ظروف شح الموارد

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

Communicable and non-communicable diseases in Africa in 2021/22

World Health Organization Africa Region; WHO Africa World Health Organization Africa Region; WHO Africa (2023) C_WHO

This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster ... the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tracks progress made with respect to disease burden reduction, elimination and eradication. It also highlights major emerging threats, opportunities and priorities in the fight against commu- nicable and non-communicable diseases in the region. It covers the period 2000-2022, but for some indicators, information is available only up to 2021. The report shows the number of reported cases for malaria and vaccine preventable diseases (meningitis, measles, yellow fever, pertussis, diphtheria, tetanus, and polio); disease incidence due to HIV, tuberculosis and four major noncommunicable diseases (cardiovas- cular diseases, cancers, diabetes and chronic respira- tory diseases). more

External Link

Obesidad: ¿Factor de riesgo o enfermedad?

C. Aguilera; Labbé, T.; Busquets, J.; et al. Revista médica de Chile (2019) CC

Obesity is a global health problem. Its worldwide prevalence has tripled between 1975 and 2016, reaching a prevalence in Chile of 34.4%, according to the National Health Survey 2016-2017. If this condition corresponds to a risk factor or primary dis... more

External Link

Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities

Bovet, P.; Chiolero, A.; Paccaud, F. et al. Public Health Reviews (2015) CC

Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the leading cause of premature mortality in low and middle income countries (LMICs). Identifying and managing individuals at high risk ... CVD is an important strategy to prevent and control CVD, in addition to multisectoral population-based interventions to reduce CVD risk factors in the entire population. Methods: We describe key public health considerations in identifying and managing individuals at high risk of CVD in LMICs. Results: A main objective of any strategy to identify individuals at high CVD risk is to maximize the number of CVD events averted while minimizing the numbers of individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and diabetes status). Opportunistic screening of CVD risk factors enables identification of persons with high CVD risk, but this strategy can be widely applied in low resource settings only if cost effective interventions are used (e.g. the WHO Package of Essential NCD interventions for primary health care in low resource settings package) and if treatment (generally for years) can be sustained, including continued availability ofaffordable medications and funding mechanisms that allow people to purchase medications without impoverishing them (e.g. universal access to health care). Thisalso emphasises the need to re-orient health systems in LMICs towards chronic diseases management. Conclusion: The large burden of CVD in LMICs and the fact that persons with high CVD can be identified and managed along cost-effective interventions mean that health systems need to be structured in a way that encourages patient registration, opportunistic screening of CVD risk factors, efficient procedures for the management of chronic conditions (e.g. task sharing) and provision of affordable treatment for those with high CVD risk. The focus needs to be in primary care because that is where most of the population can access health care and because CVD programmes can be run effectively at this level. more

Download (224)

View PDF (318)

HEARTS. Technical package for cardiovascular disease management in primary health care. Evidence-based treatment protocols

World Health Organization WHO, et al. (2018) C_WHO

In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, and only a minority of... more

Download (232)

View PDF (419)

Noncommunicable diseases in the Region of the Americas: facts and figures

Pan American Health Organization (PAHO) (2019) C_WHO

This booklet presents data on NCD mortality and prevalence of NCD risk factors, by country, for the Region of the Americas. The focus is on the 5 x 5 NCD agenda which includes the main NCDs (cardiov... more

Download (338)

View PDF (504)

Guideline: Vitamin D supplementation in pregnant women

World Health Organization (WHO) (2012) C_WHO

Vitamin D deficiency is thought to be common among pregnant women, particularly during the winter months, and has been found to be associated with an increased risk of pre-eclampsia, gestational diabetes... more

Download (464)

View PDF (793)

Botswana - Diabetes country profiles

(2016) C_WHO

World Health Organization – Diabetes country profiles, 2016.

Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 country capacity survey in the Eastern Mediterranean Region

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The report "Assessing National Capacity for the Prevention and Control of Noncommunicable Diseases" provides an overview of the capacities ... countries in the Eastern Mediterranean Region to address noncommunicable diseases (NCDs) based on a 2019 survey. It evaluates the progress of 22 countries in areas such as governance, policy implementation, health infrastructure, data collection, and healthcare resources for NCD prevention. The report highlights achievements and gaps, emphasizing the need for strengthened health systems, surveillance, and cross-sectoral collaboration to meet the WHO's global NCD targets. The findings guide further actions to reduce the burden of NCDs in the region. more

Global mapping report on multisectoral actions to strengthen the prevention and control of noncommunicable diseases and mental health conditions Experiences from around the world 2023

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The "Global mapping report on multisectoral actions to strengthen the prevention and control of noncommunicable diseases (NCDs) and mental health conditions" by the WHO provides insights into how di... more

Prevalence and factors associated with prediabetes and diabetes mellitus in Kenya: results from a national survey

Mohamed, S.F.; Mwangi M., Mutua1 M.K., et al. BMC Public Health (2018) C1

Mohamed et al. BMC Public Health 2018, 18(Suppl 3):1215 https://doi.org/10.1186/s12889-018-6053-xpre-

Diabetes self-management education interventions in the WHO African Region: A scoping review

Kumah, E.; Otchere, G.; Egyakawa Ankomah, S.; et al. PLoS One (2021) CC2

Diabetes mellitus (DM) is one of the commonest chronic diseases worldwide. Self-Management Education (SME) is regarded as a critical element of tre... more

No time to lose: Universal health coverage and the growing burden of non-communicable diseases

NCD Alliance American College of Cardiology - NCD Academy (2023) CC2

The NCD Alliance website provides information and resources on preventing and controlling non-communicable diseases (NCDs), including cardiovascular diseases, cancer, respiratory diseases, diabetes, and mental health conditions. The Alliance advocat... more

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases ... more

Toolkit for developing a multisectoral action plan for noncommunicable diseases: module 1: conducting a comprehensive assessment

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

One of the first steps in developing a multisectoral action plan (MSAP) is to use a situation analysis to provide a comprehensive assessment of the health needs, prevailing risks and the context ... the area to which the plan will apply. This will help countries, regions, provinces or cities intending to create a multisectoral action plan to align with the global commitments on targeting the four major NCDs: cardiovascular disease, diabetes, cancer and chronic respiratory diseases. more

Noncommunicable diseases - Regional framework for action

World Health Organization (WHO) Regional Office for the Eastern Mediterranean World Health Organization (WHO) Regional Office for the Eastern Mediterranean (2024) C_WHO

The WHO EMRO webpage on the "Regional framework for action" outlines strategies for addressing noncommunicable diseases (NCDs) within the Eastern Mediterranean region. The framework provides a roadmap for countries to reduce the prevalence and impact of... more

ГЛОБАЛЬНЫЙ ПЛАН ДЕЙСТВИЙ ПО ПРОФИЛАКТИКЕ НЕИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЙ И БОРЬБЕ С НИМИ

World Health Organization (WHO) World Health Organization (WHO) (2013) C_WHO

The "Global NCD action plan" provides a road map and a menu of policy options for countries to take in order to attain the 9 voluntary global targets, including that of a 25% relative reduction in p... more

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Can we prevent cardiovascular diseases in low- and middle-income countries?

Lenfant, C. Bulletin of the World Health Organization (2001) C_WHO

The article "Can we prevent cardiovascular diseases in low- and middle-income countries?" by Claude Lenfant discusses the growing threat of cardiovascular diseases (CVDs) in developing countries. It highlights that while CVD is already the leading c... more